FDA Grants Fast Track Designation to Abelacimab
The FDA granted Fast Track status to Anthos Therapeutics’ investigational monoclonal antibody, abelacimab, for treatment of patients with cancer-associated blood clots.
Currently available anticoagulants to treat cancer-associated thrombosis are limited options because of an increased risk of bleeding.
Abelacimab, which can be administered intravenously, inhibits the Factor XI enzyme that causes blood coagulation, with less risk of bleeding.
The FDA’s Fast Track designation gives drug sponsors expedited reviews for their treatments for serious medical conditions that address unmet medical needs.
Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.
July 14, 2022
